Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Amneal Pharmaceuticals, Inc. AMRX
$20.35 +0.25% Close, Oct 5, 2026 · NASDAQ · Market cap $6.48B
Strong trendInexpensive vs sector
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.49, up 7286.4% year over year.
- Over the past year the stock returned +95.7%, ahead of the S&P 500 by 79.9 percentage points.
- Earnings beat analyst estimates in each of the last 6 quarters (average surprise over the last four: +35.3%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 49%
- EPS growth (TTM, YoY)Top 1%
- FCF growth (TTM, YoY)Bottom 16%
- Revenue growth, 3-year CAGRTop 48%
- Revenue growth accelerationTop 31%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 10%
- Gross marginBottom 26%
- Operating marginTop 20%
- Cash conversion (OCF / net income)Bottom 34%
- Accruals (lower is better)Bottom 20%
- Net debt / EBITDA (lower is better)Bottom 19%
- Interest coverTop 38%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 22%
- Free-cash-flow yieldTop 31%
- EBITDA / enterprise valueTop 16%
- Sales / enterprise valueTop 38%
- P/E vs own 5-year history (lower is better)Top 30%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 24%
- 6-month returnTop 16%
- 1-year return vs S&P 500Top 17%
- Distance from 52-week highTop 8%
- Trend checklist (0–4)Top 10%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 16%
- Consecutive EPS beatsTop 12%
- Share of analysts rating BuyBottom 31%
- Upside to consensus price targetBottom 23%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 22%
- Maximum drawdown, 3 yearsTop 2%
- Beta vs S&P 500 (lower is better)Top 29%
- Net debt / EBITDA (lower is better)Bottom 19%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 7.6% | 9.3% | ↑ |
| Gross margin | 37.7% | 39.3% | ↑ |
| Operating margin | 13.2% | 12.9% | ↓ |
| FCF margin | 9.2% | 2.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 9.3% | 7.6% | ↑ | Top 49% |
| EPS growth (TTM, YoY) | 7286.4% | — | Top 1% | |
| Gross margin | 39.3% | 37.7% | ↑ | Bottom 26% |
| Operating margin | 12.9% | 13.2% | ↓ | Top 20% |
| Net margin | 5.0% | 0.1% | ↑ | — |
| Free-cash-flow margin | 2.7% | 9.2% | ↓ | — |
| Return on invested capital | 13.4% | — | Top 10% | |
| Revenue growth, 3-year CAGR | 10.9% | — | Top 48% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.28×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +10.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 4.08×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.8×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.02%
- Shareholder yield
- -0.02%
- Share count change, 1 year
- +1.8%
- Share count change, 3-year CAGR
- +28.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 6
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +35.3%
- Average 2-day reaction, last 8
- -0.2%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $23.20
- Target vs current price
- +14.0%
- Analysts with a rating
- 17
- Share rating Buy or Strong Buy
- 65%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | +34.8% | -3.1% | -3.4% | -5.8% | — |
| May 7, 2026 | +58.8% | +0.7% | -9.0% | -0.7% | +38.4% |
| Feb 27, 2026 | +16.7% | -4.7% | -8.5% | -16.8% | -14.3% |
| Oct 30, 2025 | +30.8% | -4.1% | +12.1% | +20.0% | +32.6% |
| Aug 5, 2025 | +38.9% | +2.1% | +11.1% | +20.4% | +29.3% |
| May 2, 2025 | +40.0% | +3.0% | -3.6% | -5.4% | +4.5% |
| Feb 28, 2025 | -20.0% | +3.5% | +4.5% | -1.3% | -14.6% |
| Nov 8, 2024 | +23.1% | +1.4% | +4.5% | -1.9% | -7.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $0.30 | $0.22 | +34.8% | $796.2M |
| May 7, 2026 | $0.27 | $0.17 | +58.8% | $722.5M |
| Feb 27, 2026 | $0.21 | $0.18 | +16.7% | $814.3M |
| Oct 30, 2025 | $0.17 | $0.13 | +30.8% | $784.5M |
| Aug 5, 2025 | $0.25 | $0.18 | +38.9% | $724.5M |
| May 2, 2025 | $0.21 | $0.15 | +40.0% | $695.4M |
| Feb 28, 2025 | $0.12 | $0.15 | -20.0% | $730.5M |
| Nov 8, 2024 | $0.16 | $0.13 | +23.1% | $702.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 41.7× | 64.6× | 22th | Top 22% |
| P/E (forward) | 19.9× | — | — | — |
| EV / EBITDA | 14.0× | — | — | Top 16% |
| EV / Sales | 2.93× | — | — | Top 38% |
| Free-cash-flow yield | 1.28% | — | — | Top 31% |
| Earnings yield | 2.40% | — | — | Top 22% |
P/E over the past five years
Range 36.4× – 118.9× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +95.7%
- Earnings per share growth (TTM)
- +7286.4%
- Change in P/E multiple
- -42.6%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 14
- Days above the 200-day average
- 95
- 50-day average slope (20 days)
- +3.4%
- 200-day average slope (20 days)
- +4.7%
- Distance from 50-day average
- +10.8%
- Distance from 200-day average
- +35.2%
- RSI (14)
- 65.1
- Relative volume
- 1.08×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 40.4%
- Volatility vs own 5-year history
- 44th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.74
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -0.7%
- Maximum drawdown, 3 years
- -24.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 22, 2021 | Mar 28, 2023 | -82.8% | 508 days | 325 days (Jul 15, 2024) |
| Oct 22, 2020 | Nov 30, 2020 | -27.1% | 26 days | 47 days (Feb 8, 2021) |
| Nov 12, 2024 | Apr 10, 2025 | -24.6% | 101 days | 85 days (Aug 13, 2025) |
| Feb 17, 2026 | May 19, 2026 | -22.3% | 64 days | 15 days (Jun 10, 2026) |
| Feb 8, 2021 | Feb 23, 2021 | -18.8% | 10 days | 10 days (Mar 9, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $6.48B
- P/E (TTM)
- 41.7
- EPS, diluted (TTM)
- $0.49
- Revenue (TTM)
- $3.12B
- 52-week range
- $9.56 – $21.18
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| Gross profit | $769.0M | $791.5M | $863.9M | $1.02B | $1.14B |
| Operating income | $152.7M | -$94.9M | $204.4M | $249.3M | $423.1M |
| Net income | $10.6M | -$130.0M | -$84.0M | -$116.9M | $72.1M |
| EPS (diluted) | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $702.5M | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M | $796.2M |
| Net income | -$156,000 | -$31.1M | $12.2M | $22.4M | $2.4M | $35.1M | $62.3M | $57.7M |
| EPS (diluted) | -$0.00 | -$0.10 | $0.04 | $0.07 | $0.01 | $0.11 | $0.19 | $0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $241.8M | $65.1M | $345.6M | $295.1M | $340.0M |
| Capital expenditure | -$47.7M | -$90.6M | -$69.2M | -$75.0M | -$70.1M |
| Free cash flow | $194.1M | -$25.5M | $276.4M | $220.1M | $269.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $853,000 | $0 | $0 | $0 | $2.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $127.6M
- Total assets
- $3.78B
- Total liabilities
- $3.66B
- Total debt
- $2.79B
- Net debt
- $2.66B
- Shareholders’ equity
- $33.0M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 11,289,778
- Days to cover
- 6.64
- Change vs previous report
- +6.8%
FINRA short interest, settlement date Sep 15, 2026.